Patient Safety

FDA Investigating Reports of Infections Associated with Reprocessed Urological Endoscopes

Between Jan. 1, 2017 and Feb. 20, 2021, the FDA received more than 450 MDRs describing post-procedure patient infections or other potential contamination issues involving reprocessing these endoscopes.

The U.S. Food and Drug Administration is investigating “numerous” medical device reports (MDRs) describing patient infections and other possible contamination issues possibly associated with reprocessed urological endoscopes.

These endoscopes include cystoscopes, ureteroscopes, and cystourethroscopes.

Between Jan. 1, 2017 and Feb. 20, 2021, the FDA received more than 450 MDRs describing post-procedure patient infections or other potential contamination issues involving reprocessing these endoscopes, the agency said in a letter to healthcare providers issued April 1. The FDA says it is investigating potential causes and contributing factors associated with the reported infections and contamination issues.

Some reports have indicated issues with inadequate reprocessing or maintenance. Other potential issues the FDA is evaluating include device design and reprocessing instructions on labeling.

The FDA, still early in its evaluation, believes the risk of infection is low based on available data. Two manufacturers were cited in reports that named the maker of the devices in question. However, the agency “has not concluded that such risks are limited to a particular manufacturers’ devices nor that any specific manufacturer or brand of these devices is associated with higher risks than others.”

The reports include three deaths which occurred outside of the U.S. The patients developed Pseudomonas aeruginosa infections after procedures.

One patient death involved a cystoscope, which the report said did not pass a leak test — a preventive maintenance process required to ensure the device is not damaged. Failure to ascertain that the scope was damaged could be a source of infection.

The two other reported deaths were associated with the use of a forceps/irrigation plug, an accessory component used to control water flow and enable access to the working channel of the endoscope.

“It is unknown whether or to what degree the reported infections contributed to the patient deaths, and patient co-morbidities may have been a factor,” the FDA said in its statement. “MDRs are not, by themselves, definitive evidence of a faulty or defective medical device, and cannot be used to establish or compare rates of event occurrence.”

The FDA’s announcement includes the following recommendations for healthcare providers:

  • Carefully follow the reprocessing instructions described in the manufacturer’s instructions for use.
    • Reprocessing steps should include one of the following two options:
      • Precleaning, leak testing, cleaning, disinfecting, rinsing and drying; or
      • Precleaning, leak testing, cleaning, and sterilization.
    • Be aware that reusable accessory components may have separate reprocessing instructions.
    • Be sure to follow the applicable instructions for disassembly of the endoscope and other components when reprocessing.
  • Do not use damaged devices or those that have failed a leak test, as they could be a potential source of contamination.
  • Develop schedules for routine inspection and periodic maintenance in accordance with the manufacturer’s instructions.
  • Discuss the benefits and risks associated with procedures involving reprocessed urological endoscopes with your patients.

The agency encourages healthcare providers to report any suspected adverse events experienced with cystoscopes, ureteroscopes, and cystourethroscopes.

In August 2020, the FDA updated its recommendation that duodenoscope manufacturers and healthcare facilities transition to duodenoscopes with disposable components and scopes that are fully disposable. The safety communication from the FDA followed a prior one issued in August 2019 calling for manufacturers and healthcare organizations to move to duodenoscopes that are partially or fully single-use.

More Urology Articles
‘Practical, Inexpensive, and Harmless’ Ways to Reduce Pain During Cystoscopy
Best Practices
A systematic review uncovers ways to reduce the pain of flexible cystoscopy without the use of drugs.
4 Reasons Urologists, Procurement Managers Would Switch to Single-Use Cystoscopes
Emerging Technologies
The authors of a May study investigated worldwide market readiness of single-use flexible cystoscopes through a survey of urologists and procurement managers in France, Germany, Italy, Spain, the United Kingdom, Japan, and the United States.
More From Single-Use Endoscopy

Emerging Technologies

Physicians, researchers, and other industry professionals will gather in San Diego for Digestive Disease Week 2022 after the COVID-19 pandemic forced the event to go virtual each of the past two years.

5 Things Urologists Were Talking About at AUA 2022

Endoscopy Tech

Patient engagement and advancing diversity in urologic oncology were among the topics probed over three days in New Orleans as the American Urology Association held its annual meeting.

A Matter of Time: Shifting the Healthcare Paradigm With Single-Use

Emerging Technologies

At DeviceTalks Boston, med-tech executives talk of a day when single-use endoscopy is the standard of care and reusable endoscopes are “hanging in a museum.”